Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cellectar Biosciences (CLRB) and Acer Therapeutics (ACER).
Cellectar Biosciences (CLRB)
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Cellectar Biosciences today and set a price target of $5.50. The company’s shares closed last Tuesday at $1.99.
According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 59.2% and a 59.9% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Sensei Biotherapeutics, and Ionis Pharmaceuticals.
Currently, the analyst consensus on Cellectar Biosciences is a Moderate Buy with an average price target of $5.25.
See today’s analyst top recommended stocks >>
Acer Therapeutics (ACER)
Needham analyst Serge Belanger maintained a Hold rating on Acer Therapeutics today. The company’s shares closed last Tuesday at $3.20.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of 14.0% and a 52.1% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, KalVista Pharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Acer Therapeutics is a Moderate Buy with an average price target of $10.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
